Scoping Review: Pola Penggunaan Antipsikotika Pada Pasien Skizofrenia Paranoid
DOI:
https://doi.org/10.33508/jfst.v12i2.7330Keywords:
Paranoid schizophrenia, Pattern of Antipsychotics, Monotherapy, Combination, Remission, RelapseAbstract
Paranoid schizophrenia has a better prognosis than other forms. The main sign of paranoid schizophrenia is having strong delusions or auditory hallucinations. This review article is prepared to study the patterns of antipsychotic treatment in schizophrenia patients. The literature sources include PubMed and Google Scholar over the past decade. The PICO screening procedure yielded 6 publications utilized as primary data. This review's findings suggest that the principal objective of antipsychotic treatment in people with schizophrenia is to attain remission swiftly and safely. Atypical antipsychotics are the primary treatment option for schizophrenia, specifically Risperidone, Aripiprazole, Olanzapine, Quetiapine, and Clozapine. The implementation of combination therapy is contingent upon the severity of schizophrenia symptoms. Using combinations of antipsychotics will lead to a wider range of receptor targets, which will make antipsychotics work better. In combination therapy, typical antipsychotics are utilized due to their swift alleviation of positive symptoms, including hallucinations and delusions. Paranoid schizophrenia for achieving early remission is capable of utilizing atypical monotherapy, combination of typical and atypical, combination of atypical and atypical antipsychotics in reaching remission with symptom assessments using PANSS and GAF.
Downloads
References
Akramah, S., & Harahap, M.A. 2025. Skizofrenia Paranoid. Vitalitas Medis: Jurnal Kesehatan dan Kedokteran, 2(1), 32–38. https://doi.org/10.62383/vimed.v2i1.1043.
Azizah, H., 2025. Evaluation of Antipsychotic Drug use in Paranoid Schizophrenia Patients. Indonesian Journal of Global Health Research, 7(2), 133–142. https://doi.org/10.37287/ijghr.v7i2.5178.
Saharuddin, S., Ikawati, Z., & Kristanto, C.S., 2021. Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang. Majalah Farmaseutik, 17(2), 206–216. https://doi.org/10.22146/farmaseutik.v17i2.58508.
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., et al., 2020. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 130(5), 2620–2629. https://doi.org/10.1172/JCI137244.
Chung, I.W., Kim, H., Suh, T. & Son, J.W., 2004. Effect of antipsychotics on the quality of life of schizophrenic patients in community mental health centers: conventional versus atypical antipsychotics. Clinical psychopharmacology and neuroscience, 2(1).
Fadilla, A.R., & Puspitasari, R.M., 2016. Evaluasi Ketepatan Penggunaan Antipsikotik pada Pasien Skizofrenia Rawat Inap. Sainstech Farma: Jurnal Ilmu Kefarmasian, 9(1). https://doi.org/10.37277/sfj.v9i1.87.
Hafifah, A., Puspitasari, M.I., & Sinuraya, R.K., 2018. Review Artikel : Farmakoterapi Dan Rehabilitasi Psikososial Pada Skizofrenia. Farmaka, 16(2), 210–232.
Hendra, G.A., 2020. Analisis Hubungan Kualitas Hidup Terhadap Penggunaan Kombinasi Obat Antipsikotik pada Pasien Skizofrenia. Jurnal Kesehatan Dr. Soebandi, 8(2), 128–134. https://doi.org/10.36858/jkds.v8i2.229.
Indriani, A., Ardiningrum, W., & Febrianti, Y., 2020. Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta. Majalah Farmasetika., 4. https://doi.org/10.24198/mfarmasetika.v4i0.25882.
Jesić, M.P., Jesić, A., Filipović, J.B., & Zivanović, O., 2012. Extrapyramidal syndromes caused by antipsychotics. Medicinski Pregled, 65(11–12), 521–526. https://doi.org/10.2298/mpns1212521p.
Jusuf, H., Madania, M., Ramadhani, F. N., Papeo, D.R.P., & Kalasi, M., 2024. Gambaran Penggunaan Obat Antipsikotik pada Pasien Skizofrenia di Puskesmas Kota Gorontalo. Journal Syifa Sciences and Clinical Research, 6(1). https://doi.org/10.37311/jsscr.v6i1.23849.
Kadra, G., Stewart, R., Shetty, H., MacCabe, J.H., Chang, C.K., Kesserwani, J., et al., 2018. Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology, 235(1), 281–289. https://doi.org/10.1007/s00213-017-4767-6.
Kakar, G., Mehendale, A.M., Sadh, K., Bakshi, S.S., Bodke, H., & Krishnani, H., 2023. A Phenomenal Depiction of Paranoid Schizophrenia With Auditory Hallucinations: A Case Report. Cureus. 15(9). https://doi.org/10.7759/cureus.46092.
Kay, S.R., Opler, L.A., & Lindenmayer, J.P., 1988. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry research, 23(1), pp.99-110. https://doi.org/10.1016/0165-1781(88)90038-8.
Kemenkes RI. 2021. Pedoman Pelayanan Kefarmasian pada Gangguan Jiwa. Kementerian Kesehatan Republik Indonesia.
Lee, J.S., Yun, J.Y., Kang, S.H., Lee, S.J., Choi, J.H., Nam, B., et al., 2020. Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clinical Psychopharmacology and Neuroscience, 18(3), p.386. https://doi.org/10.9758/CPN.2020.18.3.386.
Lee, Y.S., Min, K.H., Lee, S.Y., Shim, J.J., Kang, K.H., Cho, W.H., et al., 2019. The value of glycated hemoglobin as predictor of organ dysfunction in patients with sepsis. PLoS ONE, 14(5). https://doi.org/10.1371/JOURNAL.PONE.0216397.
Lubis, A., 2023. Laporan Kasus Skizofrenia Paranoid. Prima Medical Journal (Primer), 8(1) pp.1-6. https://doi.org/10.34012/pmj.v8i1.3798.
Marder, S.R., Davis, J.M., & Chouinard, G., 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. Journal of Clinical Psychiatry, 58(12), 538–546. https://doi.org/10.4088/JCP.v58n1205.
Maslim, R., 2001. Buku saku Diagnosis Gangguan Jiwa rujukan ringkas dari PPDGJ III (3rd ed.). Direktorat Kesehatan Jiwa Dirjen Pelayanan Medik.
Maylani, R.Y., Fadraersada, J., & Ramadhan, A.M., 2018. Studi Pemberian Antipsikotik terhadap Beberapa Jenis Skizofrenia di RSJD Atma Husada Mahakam Samarinda. Proceeding of Mulawarman Pharmaceuticals Conferences, 8, 267–275. https://doi.org/10.25026/mpc.v8i1.333.
Saputri, R.P., Sulistyawati, E.E., & Untari, M.K., 2018. Analisis Rasionalitas Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap RSJD Atma Husada Mahakam Samarinda Tahun 2016. In Jurnal Farmasi Indonesia (Vol. 15, Issue 1). http://doi.org/10.23917/pharmacon.v15i1.6180.
Patel, K.R., Cherian, J., Gohil, K., & Atkinson, D., 2014. Schizophrenia: overview and treatment options. A Peer-Reviewed Journal for Formulary Management, 39(9), 638–645.
Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia, 2011. Konsensus Penatalaksanaan Gangguan Skizofrenia. Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia.
Rahaya, A., & Cahaya, N., 2016. Studi Retrospektif Penggunaan Trihexyfenidil Pada Pasien Skizofrenia Rawat Inap Yang Mendapat Terapi Antipskotik Di Rumah Sakit Jiwa Sambang Lihum. Galenika Journal of Pharmacy, 2(2), 124–131.
Rissa, M.M., & Darmawan, E., 2021. Nilai PANSS-EC dan GAF Pada Pasien Gangguan Mental Psikotik yang Diterapi Atypical-Atypical Dan Atypical-Typical di Rumah Sakit Jiwa Grhasia Yogyakarta. Pharmaceutical Journal of Islamic Pharmacy, 5(1), 15. https://doi.org/10.21111/pharmasipha.v5i1.3941.
Rissa, M.M., Darmawan, E., & Siwinarni, A., 2020. Profil Penggunaan Obat Kombinasi Risperidone-Clozapine dan Risperidone dengan Antipsikotik Lain pada Pasien Gangguan Mental Psikotik di Rumah Sakit Jiwa Grhasia Yogyakarta. Jurnal Surya Medika, 5(2), 131–138. https://doi.org/10.33084/jsm.v5i2.1320.
Sagita, W., Hasni, D., & Haiga, Y., 2020. Prevalensi Tardive Dyskinesia pada Pasien Skizofrenia yang Mendapat Terapi Antipsikotik di RSJ HB Saanin Padang . Tuntas-Tuntas Riset Kesehatan, 10(1), 21–27. http://dx.doi.org/10.33846/2trik10105.
Stahl, S.M., 2021. Stahl’s Essential Psychopharmacology. Cambridge University Press. https://doi.org/10.1017/9781108975292.
Stuart, G.W., & Keliat, B.A., 2016. Prinsip dan praktik keperawatan kesehatan jiwa Stuart buku 1 : edisi Indonesia (2nd ed.). Elsevier Singapore.
Surbakti, C.I., Sinaga, T.A., & Sianipar, A.Y., 2022. Profil Penggunaan Obat Antipsikotik pada Pasien Orang dengan Gangguan Jiwa (ODGJ) di UPT. Puskesmas Helvetia Kota Medan. Journal of Pharmaceutical and Sciences, 5(2), 187–192. https://doi.org/10.36490/journal-jps.com.v5i2.115.
Suryani, D.S., Mawaddah, N., & Suhartanti, I., 2024. Asesmen Kegawatdaruratan Psikiatri Menggunakan PANSS-EC pada Pasien yang dilakukan Restrain dan Isolasi di RS Radjiman Wediodiningrat Lawang. Jurnal Kesehatan Tambusai, 5(1), 1818–1828.
Tanjung, A. I., Neherta, M., & Sarfika, R., 2022. Faktor-faktor yang Berhubungan dengan Kekambuhan Orang dengan Skizofrenia yang Berobat di Poli-Klinik Rumah Sakit Jiwa Prof. Dr. Muhammad Ildrem Medan Tahun 2021. Jurnal Ilmiah Universitas Batanghari Jambi, 22(1), 432. https://doi.org/10.33087/jiubj.v22i1.2170.
Telles-Correia, D., Barbosa, A., Cortez-Pinto, H., Campos, C., Rocha, N.B.F., & Machado, S., 2017. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World Journal of Gastrointestinal Pharmacology and Therapeutics, 8(1), 26. https://doi.org/10.4292/wjgpt.v8.i1.26.
Tiara, C., Pramesti, W., Pebriyani, U., & Alfarisi, R., 2020. Hubungan Konsep Dukungan Keluarga dengan Tingkat Kekambuhan pada Paisen Skizofrenia. Jurnal Ilmiah Kesehatan Sandi Husada, 11(1), 522–532. https://doi.org/10.35816/jiskh.v11i1.339.
Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A., 2019. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry, 76(5), 499–507. https://doi.org/10.1001/jamapsychiatry.2018.4320.
Tsou, C.C., & Huang, S.Y., 2016. Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report. Australasian Psychiatry, 24(6), 545–547. https://doi.org/10.1177/1039856216665285.
Utami, V.L., & Septa, T., 2017. Skizofrenia Paranoid Remisi Partial pada Pria Usia 35 Tahun di Rumah Sakit Jiwa Daerah Provinsi Lampung. 6(3), 123–127.
Vicario, M.H., & Hernandez, P.R., 2013. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Association.
Wijdicks, E.F.M., & Ropper, A.H., 2024. Neuroleptic Malignant Syndrome. New England Journal of Medicine, 391(12), 1130–1138. https://doi.org/10.1056/NEJMra2404606.
Yulianty, M.D., Cahaya, N., & Srikartika, V.M., 2017. Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. Jurnal Sains Farmasi & Klinis, 03(02), 153–164
Downloads
- 1 154
Published
Issue
Section
License
Copyright (c) 2025 Cahana Rastra Cotama, Yulistiani
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- All articles published Open Access will be immediately and permanently free for everyone to read and download. We are continuously working with our author communities to select the best choice of license options, currently being defined for this journal as follows: Creative Commons Attribution (BY NC SA)
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
